These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11948031)

  • 41. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
    Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
    Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III.
    Albuquerque AL; Nery LE; Villaça DS; Machado TY; Oliveira CC; Paes AT; Neder JA
    Eur Respir J; 2006 Nov; 28(5):939-44. PubMed ID: 16870665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The structural basis of airways hyperresponsiveness in asthma.
    Brown RH; Pearse DB; Pyrgos G; Liu MC; Togias A; Permutt S
    J Appl Physiol (1985); 2006 Jul; 101(1):30-9. PubMed ID: 16469934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients?
    Broeders ME; Molema J; Hop WC; Vermue NA; Folgering HT
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):449-55. PubMed ID: 12920494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of regular salbutamol on lung function and bronchial responsiveness in patients with primary ciliary dyskinesia.
    Koh YY; Park Y; Jeong JH; Kim CK; Min YG; Chi JG
    Chest; 2000 Feb; 117(2):427-33. PubMed ID: 10669686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction.
    Giannini D; Di Franco A; Bacci E; Dente FL; Taccola M; Vagaggini B; Paggiaro P
    Chest; 2000 May; 117(5):1319-23. PubMed ID: 10807817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction.
    Lavorini F; Geri P; Luperini M; Maluccio NM; Mariani L; Marmai C; Pistolesi M; Fontana GA
    Br J Clin Pharmacol; 2004 Nov; 58(5):512-20. PubMed ID: 15521899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The confounding effects of thoracic gas compression on measurement of acute bronchodilator response.
    Sharafkhaneh A; Babb TG; Officer TM; Hanania NA; Sharafkhaneh H; Boriek AM
    Am J Respir Crit Care Med; 2007 Feb; 175(4):330-5. PubMed ID: 17110648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
    Diba C; King GG; Berend N; Salome CM
    Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
    Müller V; Gálffy G; Orosz M; Kováts Z; Odler B; Selroos O; Tamási L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():93-101. PubMed ID: 26834466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longitudinal changes in lung hyperinflation in COPD.
    Park J; Lee CH; Lee YJ; Park JS; Cho YJ; Lee JH; Lee CT; Yoon HI
    Int J Chron Obstruct Pulmon Dis; 2017; 12():501-508. PubMed ID: 28223790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bronchodilator response in residual volume in irreversible airway obstruction.
    Balestra AM; Bingisser RB; Chhajed PN; Tamm M; Leuppi JD
    Swiss Med Wkly; 2008 May; 138(17-18):251-5. PubMed ID: 18481230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute bronchodilator responsiveness in bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation.
    Barisione G; Bacigalupo A; Crimi E; Brusasco V
    Chest; 2011 Mar; 139(3):633-639. PubMed ID: 20724742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bronchodilator responsiveness in patients with COPD.
    Tashkin DP; Celli B; Decramer M; Liu D; Burkhart D; Cassino C; Kesten S
    Eur Respir J; 2008 Apr; 31(4):742-50. PubMed ID: 18256071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improvements with tiotropium in COPD patients with concomitant asthma.
    Magnussen H; Bugnas B; van Noord J; Schmidt P; Gerken F; Kesten S
    Respir Med; 2008 Jan; 102(1):50-6. PubMed ID: 17920256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease.
    Taube C; Lehnigk B; Paasch K; Kirsten DK; Jörres RA; Magnussen H
    Am J Respir Crit Care Med; 2000 Jul; 162(1):216-20. PubMed ID: 10903244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Lung; 2006; 184(4):217-22. PubMed ID: 17006748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry.
    Nair A; Ward J; Lipworth BJ
    Ann Allergy Asthma Immunol; 2011 Oct; 107(4):317-22. PubMed ID: 21962091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
    Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does the mode of inhalation affect the bronchodilator response in patients with severe COPD?
    Eiser NM; Phillips C; Wooler PA
    Respir Med; 2001 Jun; 95(6):476-83. PubMed ID: 11421505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.